SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?


To: Steve Research who wrote (5378)8/26/1998 7:55:00 PM
From: Linda Kaplan  Respond to of 7041
 
ZONA dropped two points since the LAST time you said you'd be back when ZONA's at 30.

There's no comparison between "ROGAINE or MONOXODIL" and Vasomax. What hair-raising drug had the market sewn up when "ROGAINE or MONOXODIL" was released?

Linda



To: Steve Research who wrote (5378)8/26/1998 8:33:00 PM
From: Hank  Read Replies (1) | Respond to of 7041
 
"...just so I don't have to watch everyone who is short ZONA lose money:"

Given the fact that my short position is already up over 20% in less than a month, you must think short sellers are as stupid as you appear to be. Even if a miracle were to happen and ZONA began a dramatic price recovery, I'm sure those of us who are short would be smart enough to take our profits off the table. If you believe ZONA will see 30 again, then buy it until your wallet is empty. Then proceed immediately to bankruptcy court because you will lose it all. Losers always whine that they are right in the face of obvious failure.



To: Steve Research who wrote (5378)8/26/1998 11:05:00 PM
From: Bradpalm1  Read Replies (1) | Respond to of 7041
 
Stever, are you O.K.? Rogaine was a complete marketing failure for Upjohn. Further, Vasomax' clinical data was NOT compelling to say the least.

IMO, the FDA will shortly reject Vasomax' NDA review and that will be the end of Zonagen.

Bradpalm1